XVIPF (Xvivo Perfusion AB) Total Debt per Share: $0.42 (As of Mar. 2026)


XVIPF Xvivo Perfusion AB XVIPF
87 GF Score
Price $29.00
GF Value $47.23
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB Total Debt per Share?

Xvivo Perfusion AB XVIPF -1.32% 87 Total Debt per Share is $0.42 as of Mar. 2026. GuruFocus rates XVIPF with a GF Score™ of 87/100 and a GF Value™ of $47.23 (Significantly Undervalued). The stock has 2 warning signs investors should review.

$0.42 (As of Mar. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Xvivo Perfusion AB's Total Debt Per Share for the quarter that ended in Mar. 2026 was $0.42.

Xvivo Perfusion AB Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Xvivo Perfusion AB's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB Total Debt per Share Chart

Xvivo Perfusion AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.03 0.10 0.10 0.43

Xvivo Perfusion AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.37 0.42 0.43 0.42
XVIPF
87GF Score
Xvivo Perfusion AB XVIPF
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xvivo Perfusion AB Total Debt per Share Calculation

Xvivo Perfusion AB's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(12.18+1.24)/31.50
=0.43

Xvivo Perfusion AB's Total Debt Per Share for the quarter that ended in Mar. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(11.95+1.22)/31.50
=0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $0.42 mean?
Xvivo Perfusion AB (XVIPF) has a Total Debt per Share of $0.42 as of Mar. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Xvivo Perfusion AB and its competitors.
Is Xvivo Perfusion AB's Total Debt per Share too high?
Xvivo Perfusion AB's current Total Debt per Share is $0.42. Overall, Xvivo Perfusion AB has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Total Debt per Share compare to ABT and SYK?
Xvivo Perfusion AB's Total Debt per Share of $0.42 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Medical Devices & Instruments company?
A good Total Debt per Share depends on the Medical Devices & Instruments industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current Total Debt per Share is $0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $47.23, compared to a current price of $29.00 — trading 38.6% below its estimated fair value. The current Total Debt per Share is $0.42. Xvivo Perfusion AB's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Total Debt per Share is $0.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of $29.00 is trading 38.6% below its estimated GF Value™ of $47.23. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for XVIPF:

  • Total Debt per Share: $0.42
  • GF Value™: $47.23 vs. price of $29.00 (38.6% below fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
87GF Score

Get the complete analysis for XVIPF

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.00
Price
$47.23
GF Value